Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment.
Joany E KreijneAdriaan J van der MeerNanne K de BoerGerard DijkstraRachel WestSofia A W MoorselDirk J de JongC Janneke van der WoudeAnnemarie C de Vriesnull nullPublished in: Alimentary pharmacology & therapeutics (2020)
LDTA therapy is a safe and beneficial optimisation strategy in IBD patients. Continued maintenance LDTA treatment is 52% after 4 years of treatment and most commonly affected by ineffectiveness of LDTA rather than LDTA-attributed toxicity. LDTA optimisation strategy is most advantageous in patients failing thiopurine monotherapy due to AEs.